A new strategy developed by Professor Nathan Gianneschi grabs cancer-driving proteins and directs them to the cell’s disposal ...

A research team has conducted a study exploring the role of the mannose pathway in regulating cell fate decisions in low glucose environments. Their work may hold potential for novel therapeutic ...

Colorectal cancer is the third most common cancer in the United States. Although screening has led to a decrease in incidence over the past 20 years, early-onset colorectal cancer has been rising.

Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

The continuous movement of the vocal cords weakens and eventually stops as laryngeal cancer progresses. Researchers have, for ...

Despite the development of numerous cancer treatment technologies, the common goal of current cancer therapies is to eliminate cancer cells. This approach, however, faces fundamental limitations, ...

UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...

Scientists discover hidden virus in gut bacteria that may be linked to colorectal cancer development, offering new insights ...

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or delivering the wrong diagnosis.

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.